Home | Health | Cardiology
BiDil is the first drug approved by the Food and Drug Administration marketed for a single racial-ethnic group, African-Americans, in the treatment of congestive heart failure. This analysis discusses background issues to help prepare physicians to counsel patients about this controversial drug. BiDil: Assessing a Race-Based Pharmaceutical By Howard Brody, M.D., Ph.D., et al ### Annals of Family Medicine is a peer-reviewed, indexed research journal that provides a cross-disciplinary forum for new, evidence-based information affecting the primary care disciplines. Annals is sponsored by six family medical organizations, including the American Academy of Family Physicians, the American Board of Family Medicine, the Society of Teachers of Family Medicine, the Association of Departments of Family Medicine, the Association of Family Medicine Residency Directors and the North American Primary Care Research Group. Annals is published six times each year and contains original research from the clinical, biomedical, social and health services areas, as well as contributions on methodology and theory, selected reviews, essays and editorials.
Article Source: http://www.new.citynewslive.com
Complete editorial content and interactive discussion groups for each published article can be accessed free of charge on the journal's Web site, www.annfammed.org/. Contact: Kristin Robinson American Academy of Family Physicians
Please Rate this Article
5 out of 54 out of 53 out of 52 out of 51 out of 5
Not yet Rated
